{"product_id":"ormp-vrio-analysis","title":"Oramed Pharmaceuticals Inc. (ORMP): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eUnlock the secrets to Oramed Pharmaceuticals Inc. (ORMP)'s enduring success! This VRIO Analysis cuts straight to the core, revealing precisely how the firm's Value, Rarity, Inimitability, and Organization translate into sustainable competitive advantage, summarized by the key findings in \u0026amp;O4\u0026amp;. Dive in now to discover the tangible resources driving their market position and what it means for their future performance.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eOramed Pharmaceuticals Inc. (ORMP) - VRIO Analysis: 1. Proprietary Protein Oral Delivery (POD) Technology\n\u003c\/h2\u003e\n\n\u003cp\u003eYou’re looking at Oramed Pharmaceuticals Inc. (ORMP) right now, and the key takeaway is that they’ve pivoted their structure, moving development of the POD technology back in-house after terminating the OraTech joint venture, now focusing resources on a newly designed clinical trial.\u003c\/p\u003e\n\n\u003cp\u003eThe Protein Oral Delivery (POD) technology is designed to protect drug integrity and increase absorption, aiming to turn injectable biologics like insulin into oral pills. As of September 30, 2025, Oramed Pharmaceuticals Inc. reported trailing twelve-month revenue of $2M, but their balance sheet is bolstered by investment gains, showing total assets of $220.5 Million.\u003c\/p\u003e\n\n\u003ch3\u003eValue\u003c\/h3\u003e\n\u003cp\u003eThe value proposition is massive: turning injections into pills for diabetes and other chronic diseases. The concrete action to realize this value is the new clinical program. Oramed launched a 60-patient U.S. trial focused specifically on high-responder subgroups that previously showed a potential greater than 1% HbA1c reduction with ORMD-0801. This focused approach aims to de-risk the path to approval for their lead candidate, ORMD-0801. If successful, this captures a multi-billion dollar market segment currently reliant on needles.\u003c\/p\u003e\n\n\u003ch3\u003eRarity\u003c\/h3\u003e\n\u003cp\u003eHonestly, the ability to effectively shield proteins from stomach acid and ensure meaningful absorption orally is still exceptionally rare in the pharmaceutical industry. Most companies haven't cracked this code. Oramed’s POD technology represents a significant, hard-won scientific hurdle cleared, making the core capability rare among drug delivery platforms.\u003c\/p\u003e\n\n\u003ch3\u003eImitability\u003c\/h3\u003e\n\u003cp\u003eThe barrier to imitation is defintely high, primarily due to intellectual property protection. The technology is covered by patents covering methods and compositions, which creates a legal moat around the core mechanism. Furthermore, the years of clinical trial experience, even with past setbacks, create an experiential barrier that new entrants cannot easily replicate quickly.\u003c\/p\u003e\n\n\u003ch3\u003eOrganization\u003c\/h3\u003e\n\u003cp\u003eThe organizational structure has recently simplified. Oramed Pharmaceuticals Inc. will now continue development independently, having terminated the joint venture with Hefei Tianhui Biotech Co., Ltd. (HTIT) as of late 2025. The company is organizing its resources around this focused trial. They are leveraging a strong balance sheet, which saw a pre-tax net income of $65.0 Million for the nine months ended September 30, 2025, largely due to realized cash returns (like the $100 Million principal repayment from Scilex) and unrealized gains in their investment portfolio, to fund the next steps.\u003c\/p\u003e\n\u003cp\u003eHere’s a quick look at the financial context supporting the current organization:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric (As of Sept 30, 2025)\u003c\/th\u003e\n\u003cth\u003eValue (USD)\u003c\/th\u003e\n\u003cth\u003eNote\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Assets (TTM)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$220.5 Million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eUp 42% year-over-year.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Income (Pre-Tax, 9 Months)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$65.0 Million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eDriven by investment gains, not core operations.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D Expenses (9 Months)\u003c\/td\u003e\n\u003ctd\u003e$4.4 Million\u003c\/td\u003e\n\u003ctd\u003eDecreased from $4.9 Million in the prior period.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eG\u0026amp;A Expenses (9 Months)\u003c\/td\u003e\n\u003ctd\u003e$5.0 Million\u003c\/td\u003e\n\u003ctd\u003eIncreased from $4.3 Million in the prior period.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003ch3\u003eCompetitive Advantage\u003c\/h3\u003e\n\u003cp\u003eThe advantage is currently \u003cstrong\u003epotential sustained competitive advantage\u003c\/strong\u003e, contingent entirely on execution. The technology itself is rare and valuable, but the advantage only becomes sustained if Oramed Pharmaceuticals Inc. can successfully complete the new, fine-tuned Phase 3 trial and secure regulatory approval for ORMD-0801. The focus on high-responder subgroups is the key strategic lever here.\u003c\/p\u003e\n\u003cp\u003eActions to solidify this advantage include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eEnroll the 60-patient U.S. trial rapidly.\u003c\/li\u003e\n\u003cli\u003eAchieve statistically significant efficacy in the target population.\u003c\/li\u003e\n\u003cli\u003eMaintain capital discipline, leveraging investment liquidity.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eWhat this estimate hides is the inherent risk of clinical trial failure, which would immediately erode this potential advantage.\u003c\/p\u003e\n\u003cp\u003eFinance: draft 13-week cash view by Friday.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eOramed Pharmaceuticals Inc. (ORMP) - VRIO Analysis: 2. ORMD-0801 Oral Insulin Program\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eLead candidate targeting diabetes, with a refined strategy focusing on high-responder subgroups (e.g., lower BMI, older patients) for better clinical validation. Subpopulations within specific parameters such as body mass index (BMI), baseline haemoglobin A1c (Hb1Ac), and age responded well to oral insulin, showing a statistically significant reduction in HbA1c. In a prior dose-finding study, subjects dosed with ORMD-0801 8 mg QD or BID achieved greater reductions in HbA1c of \u003cstrong\u003e0.81%\u003c\/strong\u003e and \u003cstrong\u003e0.82%\u003c\/strong\u003e, respectively, compared to placebo.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eData Point\u003c\/th\u003e\n\u003cth\u003eContext\/Dose\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eHbA1c Reduction (Prior Study)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e0.81%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e8 mg QD\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHbA1c Reduction (Prior Study)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e0.82%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e8 mg BID\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHbA1c Baseline (Prior Study)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e7.5%\u003c\/strong\u003e (minimum)\u003c\/td\u003e\n\u003ctd\u003eParticipants on metformin or combination oral therapy\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHbA1c Baseline (Prior Study)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e9%-9.8%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eTotal randomized subjects in one study\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eRarity\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNo, many companies target diabetes, but a proven oral insulin delivery mechanism is unique.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eTemporary; competitors can develop similar delivery systems, but the clinical data package is unique to Oramed\/OraTech.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eOramed is independently funding a new \u003cstrong\u003e60-patient\u003c\/strong\u003e US trial to generate compelling evidence for partners. The company reported a nine-month period 2025 net income (pre-tax) of \u003cstrong\u003e$65.0 million\u003c\/strong\u003e, compared to a net loss of \u003cstrong\u003e$6.1 million\u003c\/strong\u003e in the same period last year. Total assets increased \u003cstrong\u003e42%\u003c\/strong\u003e from \u003cstrong\u003e$155.3 million\u003c\/strong\u003e to \u003cstrong\u003e$220.5 million\u003c\/strong\u003e year-over-year as of September 30, 2025.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eR\u0026amp;D expenses for the nine months ended September 30, 2025: \u003cstrong\u003e$4.4 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eG\u0026amp;A expenses for the nine months ended September 30, 2025: \u003cstrong\u003e$5.0 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eTemporary, as success hinges on the outcome of the new, smaller, targeted Phase 3 trial. The previous Phase 3 trial, ORA-D-013-1, enrolled \u003cstrong\u003e710 patients\u003c\/strong\u003e, surpassing the target of \u003cstrong\u003e675 patients\u003c\/strong\u003e. This trial randomized patients \u003cstrong\u003e2:2:1:1\u003c\/strong\u003e into four groups: \u003cstrong\u003e8 mg\u003c\/strong\u003e dosed once-daily; \u003cstrong\u003e8 mg\u003c\/strong\u003e dosed twice-daily; placebo dosed once-daily; and placebo dosed twice-daily. The trial did not meet its primary or secondary endpoints at 26 weeks.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eOramed Pharmaceuticals Inc. (ORMP) - VRIO Analysis: 3. Strategic Investment Portfolio \u0026amp; Realized Gains\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eGenerated a pre-tax net income of \u003cstrong\u003e\\$65.0 million\u003c\/strong\u003e for the nine months ended September 30, 2025, compared to a net loss of \u003cstrong\u003e\\$6.1 million\u003c\/strong\u003e in the same period last year, providing crucial non-dilutive capital.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eYes\u003c\/strong\u003e, the scale of gains from strategic, non-core assets is unusual for a clinical-stage firm.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eTemporary\u003c\/strong\u003e; the specific gains from Alpha Tau Medical Ltd. and the Scilex repayment are one-time events.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eManagement’s disciplined approach successfully realized the \u003cstrong\u003e\\$100 million\u003c\/strong\u003e principal repayment from Scilex.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eTemporary, as this cash buffer funds R\u0026amp;D and corporate flexibility until the core asset succeeds.\u003c\/p\u003e\n\n\u003cp\u003eThe financial impact of the strategic portfolio for the nine months ended September 30, 2025, is summarized below:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eAmount (9 Months Ended Sep 30, 2025)\u003c\/th\u003e\n\u003cth\u003eComparison\/Context\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Income (Pre-Tax)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\\$65.0 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eReversal from a net loss of \u003cstrong\u003e\\$6.1 million\u003c\/strong\u003e year-over-year.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eScilex Repayment Received in Period\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e\\$27 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003ePart of the total \u003cstrong\u003e\\$100 million\u003c\/strong\u003e principal repayment.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Assets\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\\$220.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eIncrease of \u003cstrong\u003e42%\u003c\/strong\u003e year-over-year from \u003cstrong\u003e\\$155.3 million\u003c\/strong\u003e.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBasic Earnings Per Share (EPS)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\\$1.30\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eCompared to a loss per share a year prior.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDiluted Earnings Per Share (EPS)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\\$1.26\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eCompared to a loss per share a year prior.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSales\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\\$2 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFor the nine-month period.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eFurther details on operating expenses and investment realization include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eR\u0026amp;D expenses decreased from \u003cstrong\u003e\\$4.9 million\u003c\/strong\u003e to \u003cstrong\u003e\\$4.4 million\u003c\/strong\u003e for the nine-months.\u003c\/li\u003e\n\u003cli\u003eG\u0026amp;A expenses increased from \u003cstrong\u003e\\$4.3 million\u003c\/strong\u003e to \u003cstrong\u003e\\$5.0 million\u003c\/strong\u003e for the nine-months.\u003c\/li\u003e\n\u003cli\u003eThe significant net income was driven by realized cash returns from Scilex Holding Company and substantial unrealized fair-value gains from equity holdings in \u003cstrong\u003eAlpha Tau Medical Ltd.\u003c\/strong\u003e and other investments.\u003c\/li\u003e\n\u003cli\u003eTotal assets growth of \u003cstrong\u003e42%\u003c\/strong\u003e reflects the influx of capital from the strategic portfolio realization.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eOramed Pharmaceuticals Inc. (ORMP) - VRIO Analysis: 4. Strategic Manufacturing \u0026amp; Supply Chain Access via HTIT\n\u003c\/h2\u003e\n\n\u003ch3\u003eValue\u003c\/h3\u003e\n\u003cp\u003eEnsures a reliable, scalable supply of oral insulin capsules for clinical trials and future commercialization activities. Allocation of combined capital of \u003cstrong\u003e$75 million\u003c\/strong\u003e for development and commercialization, with part allocated for services via a supply agreement.\u003c\/p\u003e\n\n\u003ch3\u003eRarity\u003c\/h3\u003e\n\u003cp\u003eNo, manufacturing capacity is generally available, but this is a pre-negotiated, cost-effective arrangement leveraging HTIT’s state-of-the-art facilities.\u003c\/p\u003e\n\n\u003ch3\u003eImitability\u003c\/h3\u003e\n\u003cp\u003eTemporary; the specific terms of the supply agreement with Hefei Tianhui Biotech (HTIT) are exclusive to the OraTech joint venture structure.\u003c\/p\u003e\n\n\u003ch3\u003eOrganization\u003c\/h3\u003e\n\u003cp\u003eThis capability was embedded into the OraTech joint venture structure, leveraging HTIT’s expertise in capsule production and cost-efficient manufacturing.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eJV Financial\/Structural Component\u003c\/th\u003e\n\u003cth\u003eAmount\/Percentage\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eHTIT Initial Investment in OraTech\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$60 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOramed Initial Investment in OraTech\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$15 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Combined Capital Contribution\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$75 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInitial Equity Stake (Oramed\/HTIT)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e50%\u003c\/strong\u003e each\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe operational support is formalized through the JV structure, which includes the supply agreement.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eHTIT completed Phase 3 oral insulin trial in China.\u003c\/li\u003e\n\u003cli\u003eHTIT submitted New Drug Application (NDA) to the National Medical Products Administration (NMPA) in China.\u003c\/li\u003e\n\u003cli\u003eOraTech to advance registration of oral insulin in the U.S. and other countries.\u003c\/li\u003e\n\u003cli\u003eOraTech to receive royalty payments from sales of oral insulin in China.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eCompetitive Advantage\u003c\/h3\u003e\n\u003cp\u003eTemporary, as the JV structure dictates the terms of this operational support, which is critical for advancing ORMD-0801.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eOramed Pharmaceuticals Inc. (ORMP) - VRIO Analysis: 5. Royalty Streams from Scilex Partnership\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue\u003c\/strong\u003e: Provides ongoing, low-cost revenue streams from multiple commercial products like ZTlido, ELYXYB, and GLOPERBA.\u003c\/p\u003e\n\u003cp\u003eThe royalty streams are structured as follows:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eProduct\/Agreement\u003c\/th\u003e\n\u003cth\u003eRoyalty Rate on Net Sales Worldwide\u003c\/th\u003e\n\u003cth\u003eOramed's Entitlement Share\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eZTlido (and SP-103\/successor forms)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e8%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e50%\u003c\/strong\u003e of the proceeds from the 8% royalty (from a separate agreement) and the full 8% royalty right.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGloperba and Elyxyb (and related forms)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e4%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eThe full 4% royalty right.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eSpecific royalty payment received was \u003cstrong\u003e$400,000\u003c\/strong\u003e due for \u003cstrong\u003eQ4 2024\u003c\/strong\u003e sales, with expectations for quarterly increases. Contextual sales data for the underlying products include ZTlido net sales in the range of \u003cstrong\u003e$12.0 million to $13.0 million\u003c\/strong\u003e for \u003cstrong\u003eQ1 2024\u003c\/strong\u003e, and projected combined net sales for ZTlido, Elyxyb, and Gloperba reaching \u003cstrong\u003e$74 million by 2025\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity\u003c\/strong\u003e: No, royalty rights are common, but the specific portfolio is unique to Oramed’s past deals.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability\u003c\/strong\u003e: Sustained, as long as the underlying products are on the market and the royalty agreements are in place.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization\u003c\/strong\u003e: The company maintains equity ownership in Scilex alongside the royalty rights.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eOramed held \u003cstrong\u003e12.25 million shares\u003c\/strong\u003e of Scilex common stock, which increased to \u003cstrong\u003e18.75 million shares\u003c\/strong\u003e due to warrant vesting.\u003c\/li\u003e\n\u003cli\u003eScilex repurchased \u003cstrong\u003e3,130,000 warrants\u003c\/strong\u003e from Oramed for \u003cstrong\u003e$13,000,000\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eScilex retains an option to repurchase the remaining \u003cstrong\u003e3,370,000 warrants\u003c\/strong\u003e from Oramed for \u003cstrong\u003e$14,000,000\u003c\/strong\u003e on or before \u003cstrong\u003eDecember 31, 2025\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage\u003c\/strong\u003e: Sustained, offering a financial floor independent of clinical trial success.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eOramed Pharmaceuticals Inc. (ORMP) - VRIO Analysis: 6. Robust Intellectual Property Portfolio\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Protects the core POD technology, including methods for oral administration of proteins like insulin and exenatide, plus improved protease inhibitors.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e \u003cstrong\u003eYes\u003c\/strong\u003e, the specific breadth covering multiple proteins and delivery mechanisms is hard to replicate.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e \u003cstrong\u003eSustained\u003c\/strong\u003e; patent protection is the strongest form of defense in this sector.\u003c\/p\u003e\n\u003cp\u003eThe intellectual property portfolio size and scope provide a quantifiable measure of this resource:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eData Point 1 (As of Dec 31, 2023)\u003c\/th\u003e\n\u003cth\u003eData Point 2 (As of Jan 5, 2022)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Patents Held\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e117\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e88\u003c\/strong\u003e Granted\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatent Applications Pending\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e38\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e35\u003c\/strong\u003e Pending\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePotential Expiration Range (Pending)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e2026 and 2039\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe portfolio includes patents granted by offices such as the United States, European, Japanese, and Chinese patent offices.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e The IP was transferred to OraTech, but Oramed retains a majority stake, protecting its long-term interest. This structure is supported by significant financial commitment:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eOramed and HTIT will contribute a combined \u003cstrong\u003e$75 million\u003c\/strong\u003e in capital to OraTech.\u003c\/li\u003e\n\u003cli\u003eOramed shareholders are expected to receive a cash dividend of approximately \u003cstrong\u003e$0.25 per share\u003c\/strong\u003e related to the OraTech distribution.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e \u003cstrong\u003eSustained\u003c\/strong\u003e, as long as patents remain in force.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eOramed Pharmaceuticals Inc. (ORMP) - VRIO Analysis: 7. Financial Flexibility from Strategic Asset Realization\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Total assets grew \u003cstrong\u003e42%\u003c\/strong\u003e year-over-year to \u003cstrong\u003e$220.5 million\u003c\/strong\u003e as of September 30, 2025, providing a strong balance sheet, up from \u003cstrong\u003e$155.3 million\u003c\/strong\u003e in the prior year period.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eFinancial Metric (Nine Months Ended Sept 30, 2025)\u003c\/th\u003e\n\u003cth\u003eAmount (USD)\u003c\/th\u003e\n\u003cth\u003ePrior Period Comparison\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Income (Pre-tax)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$65.0 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eCompared to a net loss of \u003cstrong\u003e$6.1 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Assets\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$220.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e42%\u003c\/strong\u003e YoY increase\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eScilex Full Principal Repayment\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$100 million\u003c\/strong\u003e (Total)\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e$27 million\u003c\/strong\u003e received in the period\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBasic Earnings Per Share (EPS)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1.30\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDiluted Earnings Per Share (EPS)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1.26\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e No, asset growth is common, but the source (investment realization vs. operations) is noteworthy.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Temporary; this specific asset base is a result of past transactions.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e The strong cash position allows for continued R\u0026amp;D spending while managing G\u0026amp;A expenses, as evidenced by the following operating expense structure for the nine months ended September 30, 2025:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eR\u0026amp;D expenses: \u003cstrong\u003e$4.4 million\u003c\/strong\u003e, a decrease from $4.9 million in the prior comparable period.\u003c\/li\u003e\n\u003cli\u003eG\u0026amp;A expenses: \u003cstrong\u003e$5.0 million\u003c\/strong\u003e, an increase from $4.3 million in the prior comparable period.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary, as the cash balance will be deployed or used to fund operations.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eOramed Pharmaceuticals Inc. (ORMP) - VRIO Analysis: 8. Corporate Structure for Value Unlocking\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e The spin-off of OraTech, expected to go public on Nasdaq, allows for the separation and independent valuation of the core technology platform. Oramed plans to distribute the majority of its expected 50% stake in OraTech to ORMP shareholders via a dividend, coinciding with the public listing.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e No, spin-offs are a known strategy, but the direct distribution of majority OraTech holdings to Oramed shareholders is a unique mechanism. A planned cash dividend of approximately $0.25 per share is intended to help offset any potential tax liabilities associated with the OraTech stock distribution.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Temporary; the structure is set, but competitors could attempt similar maneuvers. The initial capital structure involved a combined investment of $75 million from Oramed and HTIT into OraTech.\u003c\/p\u003e\n\n\u003cp\u003eThe capital structure and initial funding are detailed below:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eComponent\u003c\/td\u003e\n\u003ctd\u003eDetail\u003c\/td\u003e\n\u003ctd\u003eAmount\/Percentage\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eOraTech Ownership (Oramed's Expected Stake)\u003c\/td\u003e\n\u003ctd\u003eMajority Stake via Dividend\u003c\/td\u003e\n\u003ctd\u003eExpected 50%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInitial Capital Contribution (Total)\u003c\/td\u003e\n\u003ctd\u003eOramed + HTIT\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$75 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInitial HTIT Investment\u003c\/td\u003e\n\u003ctd\u003eCash Contribution\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$60 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInitial Oramed Investment\u003c\/td\u003e\n\u003ctd\u003eCash Contribution\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$15 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePlanned Cash Dividend per Share\u003c\/td\u003e\n\u003ctd\u003eTo offset potential tax liabilities\u003c\/td\u003e\n\u003ctd\u003e~$0.25 per share\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePlanned Post-IPO Investment (ORMP)\u003c\/td\u003e\n\u003ctd\u003eAdditional Capital\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$7.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e The structure was approved by shareholders and is designed to reward them directly with a stake in the pure-play entity. Oramed reported $142 million in cash and equivalents and short-term investments at the end of 2024. For the nine months ended September 30, 2025, Oramed reported net income (pre-tax) of $65.0 million.\u003c\/p\u003e\n\n\u003cp\u003eKey organizational and financial components supporting the structure include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003ePlanned cash dividend of approximately $0.25 per share.\u003c\/li\u003e\n\u003cli\u003eOramed's expected majority holding in OraTech to be distributed via dividend, coinciding with Nasdaq listing.\u003c\/li\u003e\n\u003cli\u003eOraTech to receive royalty payments from oral insulin sales in China following Marketing Authorization Application submission.\u003c\/li\u003e\n\u003cli\u003eOramed's Q4 2024 royalty revenue from Scilex products: $400,000.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary, as the value realization is tied to the successful IPO of OraTech.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eOramed Pharmaceuticals Inc. (ORMP) - VRIO Analysis: 9. Management's Expertise in Financial Engineering and Clinical Refinement\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e The ability to pivot from the January 2023 Phase 3 trial failure of ORMD-0801 to a refined clinical strategy, evidenced by the subsequent announcement to reinitiate a pivotal trial based on subset analysis, while simultaneously generating significant investment returns, culminating in a pre-tax net income of \u003cstrong\u003e$65.0 million\u003c\/strong\u003e for the nine months ended September 30, 2025.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e \u003cstrong\u003eYes\u003c\/strong\u003e, the combination of financial acumen driving the \u003cstrong\u003e$65.0 million\u003c\/strong\u003e pre-tax net income and the clinical focus to re-evaluate and proceed after a primary endpoint miss is rare in small-cap pharma.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e \u003cstrong\u003eSustained\u003c\/strong\u003e; this is rooted in the experience of leadership like CEO Nadav Kidron, who co-founded the company in \u003cstrong\u003e2006\u003c\/strong\u003e and led it to be the first to conduct Phase 3 trials under the FDA for oral insulin.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e The leadership team is clearly organized around maximizing shareholder value through both operational and financial levers, as demonstrated by the strategic management of investment assets alongside clinical program adjustments.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e \u003cstrong\u003eSustained\u003c\/strong\u003e, as it is a human capital resource based on a proven track record of navigating significant clinical setbacks while delivering strong financial performance through investment realization.\u003c\/p\u003e\n\u003cp\u003eThe financial engineering expertise is quantified by the following results for the nine months ended September 30, 2025:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eFinancial Metric\u003c\/th\u003e\n\u003cth\u003eAmount (9M Ended Sept 30, 2025)\u003c\/th\u003e\n\u003cth\u003eComparative\/Contextual Data\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePre-tax Net Income\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$65.0 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eCompared to a net loss of \u003cstrong\u003e$6.1 million\u003c\/strong\u003e in the same period last year.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Assets\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$220.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAn increase of \u003cstrong\u003e42%\u003c\/strong\u003e year-over-year from \u003cstrong\u003e$155.3 million\u003c\/strong\u003e.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFinancial Income, net\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$74,278 thousand\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eReflecting fair value gains primarily on Alpha Tau and Scilex exposures.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eScilex Principal Repayment\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$100 million\u003c\/strong\u003e (Total)\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e$27 million\u003c\/strong\u003e received during the period.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D Expenses\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$4.4 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eA decrease from \u003cstrong\u003e$4.9 million\u003c\/strong\u003e in the prior year period.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe clinical refinement and strategic pivot are characterized by the following actions post-Phase 3 failure:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eDiscontinuation of oral insulin clinical activities for Type 2 Diabetes (T2D) was initially expected following the January 2023 trial miss.\u003c\/li\u003e\n\u003cli\u003eIn-depth review of the trial data from the failed trial (ORA-D-013-1) was completed.\u003c\/li\u003e\n\u003cli\u003eDiscovery that the oral insulin candidate was effective in particular patient subsets based on parameters such as Body Mass Index (BMI), baseline Haemoglobin A1c (HbA1c), and age.\u003c\/li\u003e\n\u003cli\u003eAnnouncement of the intention to reinitiate a Phase III trial in the U.S. based on these refined patient parameters.\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516225249429,"sku":"ormp-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/ormp-vrio-analysis.png?v=1740202623","url":"https:\/\/dcf-model.com\/pt\/products\/ormp-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}